Hospital
Mcleod Loris Seacoast Hospital
Mcleod Loris Seacoast Hospital was paid $24.76M by Medicaid between Jan 2018 and Dec 2024, across 252 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 15% of everything it billed.
33Billing provider infoMCLEOD LORIS SEACOAST HOSPITAL
LORIS, SC 29569
LORIS, SC 29569
33aNPI1306123344assigned 11/04/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$24.76M
24GClaims875,791
24DCodes billed252
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#15 of 115
Median peer was paid$2.47M
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ERVIN, SAMUEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 102,357 | $2.20M | |
| 2019 | 117,914 | $2.67M | |
| 2020 | 127,850 | $2.81M | |
| 2021 | 142,593 | $3.80M | |
| 2022 | 136,967 | $4.71M | |
| 2023 | 130,412 | $4.45M | |
| 2024incomplete | 117,698 | $4.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 15% | 53,882 | 42,768 | $3.78M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 54,138 | 48,883 | $3.31M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 11% | 49,951 | 12,473 | $2.65M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6.6% | 9,367 | 8,564 | $1.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.9% | 36,412 | 32,652 | $1.46M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.0% | 9,064 | 8,425 | $997K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 8,190 | 7,758 | $845K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.2% | 4,231 | 3,962 | $536K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 14,260 | 11,629 | $524K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 6,363 | 5,773 | $524K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.9% | 7,399 | 7,123 | $470K |
| 81001 | 1.8% | 21,163 | 19,116 | $456K |
240 more codes
| J7030 | Infusion, normal saline solution , 1000 cc | 1.6% | 4,009 | $400K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 10,503 | $372K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 24,766 | $340K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 11,070 | $324K |
| A9585 | Injection, gadobutrol, 0.1 ml | 1.3% | 438 | $315K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 14,962 | $294K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 2,917 | $277K |
| 81025 | 1.0% | 12,987 | $258K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,488 | $223K |
| 99285 | Emergency room visit (most serious) | <1% | 13,484 | $199K |
| 81003 | <1% | 7,174 | $192K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,296 | $177K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,709 | $176K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,936 | $164K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,821 | $154K |
| 73610 | <1% | 2,029 | $153K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,734 | $148K |
| 73130 | <1% | 1,463 | $131K | |
| 73630 | <1% | 2,345 | $121K | |
| 87070 | <1% | 1,545 | $115K | |
| 36416 | <1% | 6,783 | $115K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,467 | $113K |
| 73564 | <1% | 2,116 | $112K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 10,390 | $104K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,739 | $104K |
| 59025 | Fetal non-stress test | <1% | 2,463 | $100K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,345 | $99K |
| 97113 | <1% | 1,905 | $90K | |
| 71250 | <1% | 544 | $87K | |
| 73030 | <1% | 1,661 | $86K | |
| 73110 | <1% | 1,170 | $85K | |
| 74018 | <1% | 2,080 | $81K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 167 | $78K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,333 | $74K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,906 | $70K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,008 | $67K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 688 | $65K |
| 87210 | <1% | 872 | $64K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,736 | $63K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,735 | $58K |
| 72100 | <1% | 1,511 | $54K | |
| 97161 | <1% | 3,101 | $52K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,791 | $51K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 945 | $49K |
| 87077 | <1% | 2,263 | $48K | |
| 97116 | <1% | 4,923 | $45K | |
| G0378 | Hospital observation service, per hour | <1% | 5,122 | $42K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 369 | $41K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,608 | $38K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 370 | $37K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,261 | $36K |
| 82948 | <1% | 4,940 | $36K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,759 | $33K |
| 93971 | <1% | 394 | $32K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,845 | $32K |
| 12001 | <1% | 213 | $31K | |
| 73502 | <1% | 938 | $30K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,626 | $29K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 586 | $29K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 32 | $27K |
| 97162 | <1% | 1,199 | $27K | |
| 80053 | Comprehensive metabolic panel | <1% | 20,075 | $23K |
| 72040 | <1% | 418 | $23K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,783 | $21K |
| 73140 | <1% | 151 | $20K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 97 | $19K |
| 88304 | <1% | 442 | $18K | |
| 96376 | <1% | 3,887 | $17K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,386 | $17K |
| 87807 | <1% | 735 | $16K | |
| 87430 | <1% | 1,205 | $15K | |
| 76642 | <1% | 327 | $13K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 399 | $13K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,190 | $13K |
| 73080 | <1% | 188 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,153 | $13K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,168 | $13K |
| 86850 | <1% | 1,811 | $11K | |
| 73090 | <1% | 98 | $9K | |
| 76536 | <1% | 97 | $9K | |
| 73560 | <1% | 306 | $8K | |
| 76770 | <1% | 85 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,693 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,924 | $7K |
| 82565 | <1% | 1,255 | $7K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,088 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 24 | $6K |
| 85027 | <1% | 3,322 | $6K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,793 | $6K |
| 10060 | <1% | 68 | $6K | |
| 72141 | <1% | 17 | $6K | |
| 80047 | <1% | 2,009 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,433 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 106 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 747 | $6K |
| 92523 | <1% | 75 | $5K | |
| J3490 | Unclassified drugs | <1% | 3,449 | $5K |
| 74022 | <1% | 195 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,819 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,500 | $5K |
| 83735 | <1% | 10,843 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,983 | $4K |
| 71101 | <1% | 53 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,101 | $4K |
| 97533 | <1% | 4,831 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 241 | $4K |
| 71271 | <1% | 37 | $4K | |
| 97165 | <1% | 142 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,059 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,147 | $3K |
| 70486 | <1% | 73 | $3K | |
| 77062 | <1% | 14 | $3K | |
| 84484 | <1% | 11,070 | $3K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 549 | $3K |
| 87040 | <1% | 3,466 | $3K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 852 | $3K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 372 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,490 | $2K |
| 85610 | <1% | 5,788 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,190 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,332 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,443 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,288 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 392 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 624 | $2K |
| 83880 | <1% | 3,652 | $2K | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 96 | $2K |
| 82803 | <1% | 496 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,778 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 610 | $2K |
| 97166 | <1% | 79 | $1K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 292 | $1K |
| 94760 | <1% | 1,484 | $1K | |
| 12011 | <1% | 14 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,396 | $1K |
| 94644 | <1% | 729 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,102 | $1K |
| 80076 | <1% | 3,792 | $1K | |
| 92526 | <1% | 59 | $1K | |
| 83690 | <1% | 8,329 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,451 | $1K |
| 86900 | <1% | 2,671 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 27 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 31 | $1K |
| 73590 | <1% | 29 | $880.86 | |
| 77066 | Tomosynthesis, mammo | <1% | 39 | $863.39 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 52 | $854.78 |
| 83605 | <1% | 3,773 | $795.87 | |
| 84702 | <1% | 1,864 | $773.58 | |
| 76775 | <1% | 13 | $735.71 | |
| A9270 | Non-covered item or service | <1% | 4,322 | $665.95 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,534 | $663.18 |
| 85730 | <1% | 4,232 | $529.24 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,164 | $528.67 |
| 85018 | <1% | 149 | $463.20 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 175 | $451.99 |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 13 | $447.20 |
| 93017 | <1% | 14 | $430.59 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,261 | $424.36 |
| 97164 | <1% | 37 | $421.40 | |
| 90715 | <1% | 453 | $395.35 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,876 | $375.47 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 403 | $370.75 |
| 80061 | Lipid panel | <1% | 1,813 | $365.97 |
| 85379 | <1% | 1,485 | $335.39 | |
| 82270 | <1% | 26 | $333.16 | |
| C1769 | Guide wire | <1% | 2,260 | $311.21 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,080 | $290.73 |
| 87186 | <1% | 2,704 | $286.08 | |
| 97168 | <1% | 26 | $247.44 | |
| 82077 | <1% | 1,464 | $215.71 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 831 | $172.29 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 99 | $168.56 |
| 80320 | <1% | 556 | $164.59 | |
| 86901 | <1% | 2,670 | $133.95 | |
| 85014 | <1% | 75 | $131.09 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $119.61 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 378 | $111.88 |
| 84100 | <1% | 285 | $93.68 | |
| 84439 | <1% | 1,123 | $92.41 | |
| 80143 | <1% | 668 | $87.03 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,238 | $84.34 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 317 | $72.44 |
| 87205 | <1% | 385 | $64.48 | |
| 86140 | <1% | 656 | $59.40 | |
| 80179 | <1% | 565 | $51.12 | |
| 83655 | <1% | 159 | $50.81 | |
| 85651 | <1% | 838 | $45.42 | |
| 72131 | <1% | 14 | $40.40 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,308 | $37.91 |
| 82550 | <1% | 228 | $32.00 | |
| 82607 | <1% | 78 | $26.63 | |
| 94664 | <1% | 326 | $25.61 | |
| 82746 | <1% | 29 | $24.14 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 519 | $23.75 |
| 82728 | <1% | 92 | $22.36 | |
| 83550 | <1% | 52 | $14.35 | |
| 83540 | <1% | 154 | $10.65 | |
| 85046 | <1% | 68 | $9.17 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 251 | $9.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 43 | $8.31 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 297 | $5.98 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 287 | $5.63 |
| 85652 | <1% | 415 | $4.76 | |
| 84156 | <1% | 16 | $4.73 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 99 | $4.30 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 111 | $0.24 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 263 | $0.17 |
| 36902 | 0% | 604 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 31 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 13 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 40 | $0.00 |
| 84703 | 0% | 27 | $0.00 | |
| 74420 | 0% | 16 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 115 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 242 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 12 | $0.00 |
| 88342 | 0% | 41 | $0.00 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 31 | $0.00 |
| 36907 | 0% | 14 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 55 | $0.00 |
| J9047 | Injection, carfilzomib, 1 mg | 0% | 12 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 17 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 15 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 17 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 35 | $0.00 |
| 84132 | 0% | 37 | $0.00 | |
| 80329 | 0% | 35 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 30 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 101 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 47 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 69 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 57 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 124 | $0.00 |
| 87641 | 0% | 67 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 59 | $0.00 |
| 29125 | 0% | 12 | $0.00 | |
| 36600 | 0% | 18 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 29 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERVIN, SAMUEL (SR VP AND CFO)
Parent organizationMCLEOD HEALTH, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.